

## THERAPEUTICS VS TOTAL AMR R&D INVESTMENT



### FUNDING

Almost 3.1 billion USD

22% of total funding

3 times more than Vaccines & Diagnostics

\$2.2 for every \$10 invested in AMR R&D



%, million USD

## FUNDERS

81%

US 47%


EU 19%

UK 3%


Philanthropic organisations\* 12%

Country amounts exclude \*Philanthropic organisations & private non-profits

68% of funding for AMR therapeutics comes from top 5 funders



Funding Distributor Contributions\*\*



\*\*Includes contributions to global partnerships like CARB-X, GARDP & AMR Action Fund

## INSTITUTION TYPES


FUNDING

39% for SMEs

38% for universities

23% for others

Close to equal % funding for SMEs and universities



%, million USD

## INFECTIOUS AGENTS & DISEASES

57%

36% Critical


20% High

1% Medium

57% of funding for AMR therapeutics is targeted towards WHO bacterial priority pathogens

5% TARGETS ANTIFUNGALS

57% IS TARGETED TOWARDS SPECIFIC DISEASES




Others: Virus, Parasites, Not specified & not applicable pathogens

GITs: Gastrointestinal tract Infections | STIs: Sexually transmissible infections | UTIs: Urinary tract Infections | RTIs: Respiratory tract Infections | TB: Tuberculosis

## SECTORS

The majority of investments target human health

Cross-sectoral projects that span two or more sectors make up only 0.3% funding for AMR therapeutics R&D



### GAPS

### OPPORTUNITIES

### RECOMMENDATIONS

#### TARGET PRIORITY PATHOGENS

Increase support for R&D targeting priority pathogens of all types, including fungal pathogens

#### SET TARGETS

Establish targets for AMR R&D based on priority needs

#### FUNDING PARTNERSHIPS

Focus on developing funding partnerships to create diversity in funding streams

#### EVALUATION & ASSESSMENT

+ Further evaluation of the link between investment in AMR therapeutics and impact on the pipeline of products is needed

#### R&D ALIGNMENT

+ Align R&D of therapeutics, diagnostics, and vaccines targeting the same pathogens and/or diseases

#### DEVELOPMENT

+ Increase support for development of therapeutics across the full One Health spectrum, including for alternatives to antibiotics

### Want to know more?

globalamrhub@dzif.de

<https://globalamrhub.org/>

Global AMR R&D Hub

GlobalAMRHub

